Cited by

• Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax).

  Huang CY, Kinney RM, Livengood JA, Bolling B, Arguello JJ, Luy BE, Silengo SJ, Boroughs KL, Stovall JL, Kalanidhi AP, Brault AC, Osorio JE, Stinchcomb DT. Huang CY, et al. PLoS Negl Trop Dis. 2013 May 30;7(5):e2243. doi: 10.1371/journal.pntd.0002243. Print 2013. PLoS Negl Trop Dis. 2013. PMID: 23738026 Free PMC article.
• Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

  Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, Silengo S, Scott J, Boroughs KL, Stovall JL, Luy BE, Arguello J, Beatty ME, Santangelo J, Gordon GS, Huang CY, Stinchcomb DT. Osorio JE, et al. Lancet Infect Dis. 2014 Sep;14(9):830-8. doi: 10.1016/S1473-3099(14)70811-4. Epub 2014 Jul 23. Lancet Infect Dis. 2014. PMID: 25087476 Free PMC article. Clinical Trial.
• Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.

  Huang CY, Butrapet S, Tsuchiya KR, Bhamarapravati N, Gubler DJ, Kinney RM. Huang CY, et al. J Virol. 2003 Nov;77(21):11436-47. doi: 10.1128/jvi.77.21.11436-11447.2003. J Virol. 2003. PMID: 14557629 Free PMC article.
• Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine.

  Huang CY, Butrapet S, Pierro DJ, Chang GJ, Hunt AR, Bhamarapravati N, Gubler DJ, Kinney RM. Huang CY, et al. J Virol. 2000 Apr;74(7):3020-8. doi: 10.1128/jvi.74.7.3020-3028.2000. J Virol. 2000. PMID: 10708416 Free PMC article.
• Dengue and dengue hemorrhagic fever.

  Gubler DJ. Gubler DJ. Clin Microbiol Rev. 1998 Jul;11(3):480-96. doi: 10.1128/CMR.11.3.480. Clin Microbiol Rev. 1998. PMID: 9665979 Free PMC article. Review.